PURPOSE: To investigate whether patients with metastatic renal cell carcinoma benefit from sequential therapies with the tyrosine kinase inhibitors (TKIs) sorafenib and sunitinib. PATIENTS AND METHODS: A total of 89 patients were treated in nine German centres between 2002 and 2009. The TKI sequence started as first-, second- or third-line therapy after prior chemo- or immunotherapy. When progression was diagnosed, treatment was switched to the second TKI until further progression. RESULTS: Overall progression-free survival (PFS) of patients receiving sunitinib followed by sorafenib shows no statistically significant difference to patients receiving sorafenib followed by sunitinib (15.4 months vs. 12.1 months). The secondary use of sorafenib resulted in a median PFS of 3.8 months if the TKI sequence had been started as a first-line treatment and of 3.5 months if the TKI sequence had been started second-line treatment. The secondary use of sunitinib resulted in a median PFS of 3.4 and 4.0 months, respectively. OS was 28.8 months for all patients, without a statistically significant difference between the two groups. CONCLUSIONS: This study endorses the notion of a clinical benefit of the sequential use of sorafenib and sunitinib and supports observations from previous studies. In terms of the optimal succession of the two TKIs, the study does not allow a definite answer.
PURPOSE: To investigate whether patients with metastatic renal cell carcinoma benefit from sequential therapies with the tyrosine kinase inhibitors (TKIs) sorafenib and sunitinib. PATIENTS AND METHODS: A total of 89 patients were treated in nine German centres between 2002 and 2009. The TKI sequence started as first-, second- or third-line therapy after prior chemo- or immunotherapy. When progression was diagnosed, treatment was switched to the second TKI until further progression. RESULTS: Overall progression-free survival (PFS) of patients receiving sunitinib followed by sorafenib shows no statistically significant difference to patients receiving sorafenib followed by sunitinib (15.4 months vs. 12.1 months). The secondary use of sorafenib resulted in a median PFS of 3.8 months if the TKI sequence had been started as a first-line treatment and of 3.5 months if the TKI sequence had been started second-line treatment. The secondary use of sunitinib resulted in a median PFS of 3.4 and 4.0 months, respectively. OS was 28.8 months for all patients, without a statistically significant difference between the two groups. CONCLUSIONS: This study endorses the notion of a clinical benefit of the sequential use of sorafenib and sunitinib and supports observations from previous studies. In terms of the optimal succession of the two TKIs, the study does not allow a definite answer.
Authors: Ila Tamaskar; Jorge A Garcia; Paul Elson; Laura Wood; Tarek Mekhail; Robert Dreicer; Brian I Rini; Ronald M Bukowski Journal: J Urol Date: 2007-11-12 Impact factor: 7.450
Authors: Walter M Stadler; Robert A Figlin; David F McDermott; Janice P Dutcher; Jennifer J Knox; Wilson H Miller; John D Hainsworth; Charles A Henderson; Jeffrey R George; Julio Hajdenberg; Tamila L Kindwall-Keller; Marc S Ernstoff; Harry A Drabkin; Brendan D Curti; Luis Chu; Christopher W Ryan; Sebastien J Hotte; Chenghua Xia; Lisa Cupit; Ronald M Bukowski Journal: Cancer Date: 2010-03-01 Impact factor: 6.860
Authors: M P Sablin; S Negrier; A Ravaud; S Oudard; C Balleyguier; J Gautier; C Celier; J Medioni; B Escudier Journal: J Urol Date: 2009-05-17 Impact factor: 7.450
Authors: Christian Eichelberg; Roman Heuer; Felix K Chun; Kristin Hinrichs; Mario Zacharias; Hartwig Huland; Hans Heinzer Journal: Eur Urol Date: 2008-08-08 Impact factor: 20.096
Authors: Martin E Gore; Cezary Szczylik; Camillo Porta; Sergio Bracarda; Georg A Bjarnason; Stéphane Oudard; Subramanian Hariharan; Se-Hoon Lee; John Haanen; Daniel Castellano; Eduard Vrdoljak; Patrick Schöffski; Paul Mainwaring; Alejandra Nieto; Jinyu Yuan; Ronald Bukowski Journal: Lancet Oncol Date: 2009-07-15 Impact factor: 41.316
Authors: Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Staehler; Sylvie Negrier; Christine Chevreau; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Sibyl Anderson; Gloria Hofilena; Minghua Shan; Carol Pena; Chetan Lathia; Ronald M Bukowski Journal: J Clin Oncol Date: 2009-05-18 Impact factor: 44.544
Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Roberto Pili; Georg A Bjarnason; Xavier Garcia-del-Muro; Jeffrey A Sosman; Ewa Solska; George Wilding; John A Thompson; Sindy T Kim; Isan Chen; Xin Huang; Robert A Figlin Journal: J Clin Oncol Date: 2009-06-01 Impact factor: 44.544
Authors: C Porta; G Tortora; C Linassier; K Papazisis; A Awada; D Berthold; J P Maroto; T Powles; M De Santis Journal: Med Oncol Date: 2011-07-07 Impact factor: 3.064
Authors: M R Matrana; C Duran; A Shetty; L Xiao; B J Atkinson; P Corn; L C Pagliaro; R E Millikan; C Charnsangave; E Jonasch; N M Tannir Journal: Eur J Cancer Date: 2013-06-26 Impact factor: 9.162
Authors: T Wahlgren; U Harmenberg; P Sandström; S Lundstam; J Kowalski; M Jakobsson; R Sandin; B Ljungberg Journal: Br J Cancer Date: 2013-03-26 Impact factor: 7.640